Lindsey Shapiro, PhD, science writer —

A global clinical trial evaluating a pulmonary artery denervation (PADN) device in people with pulmonary hypertension (PH) associated with left heart disease has launched in Europe, with the first two patients enrolled at a hospital in Portugal, Pulnovo Medical, the device’s developer, announced. These two adults have undergone…

An advisory committee of the European Medicines Agency (EMA) is recommending that Winrevair (sotatercept) be approved for the treatment of pulmonary arterial hypertension (PAH) in the Europe Union. Specifically, the Committee for Medicinal Products for Human Use (CHMP) issued an opinion recommending that Winrevair to be used in…

Pulmonary arterial hypertension (PAH) patients enrolled in a Phase 2b clinical trial testing AV-101, an inhaled formulation of imatinib, entered the trial with significant disease despite use of triple background therapy, according to data shared by developer Aerovate Therapeutics. The company said the study population will allow for…

AER-901, a new inhaled formulation of imatinib delivered via a specialized device, was predicted to reach 2-3 times higher levels in the lung tissue over standard inhalers among people with forms of pulmonary hypertension (PH), according to new data from Aerami Therapeutics, its developer. Having been proven to…

Researchers have identified two inflammation-related genes — SELE and CCL20 — whose activity could serve as diagnostic biomarkers for the development of pulmonary hypertension (PH) in people with COVID-19. Further, the team also identified molecules that target these biomarkers as possible therapeutic approaches for managing the complication. Overall, the…

Reduced exercise capacity appeared to be a consequence of cardiac and pulmonary changes, but not skeletal muscle alterations, in rat models of pulmonary hypertension (PH), according to recent research. While no functional problems with muscles could be observed despite obvious impairments in exercise capacity, significant cardiopulmonary dysfunction was already present.

As of April 15, Opsynvi (macitentan and tadalafil) — the first single-tablet treatment combination approved by the U.S. Food and Drug Administration (FDA) for pulmonary arterial hypertension (PAH) — is available to eligible patients in the U.S. through a specialty pharmacy network. With its launch, PAH patients who…

Despite more women being affected by pulmonary hypertension (PH), men with the cardiovascular disease had worse right ventricular function and lower odds of transplant-free survival relative to their female counterparts, a study found. In a large group of patients with various types of PH, sex differences in function of…

The U.S. Food and Drug Administration (FDA) has approved once-daily, fixed-dose tablets containing a combination of macitentan and tadalafil — to be marketed under the brand name Opsynvi — to treat adults with pulmonary arterial hypertension (PAH). The approval marks the first single-tablet treatment combination to become available…

Higher blood levels of the sclerostin protein were linked to cardiac abnormalities and an elevated risk of pulmonary hypertension (PH) in patients with kidney failure, according to a recent study. While sclerostin itself did not increase mortality risk, the presence of PH was a significant predictor of mortality…

An investigational fixed-dose combination of macitentan and tadalafil in a single tablet (M/T STCT) led to improvements in blood flow and reductions in a biomarker of heart failure for people with pulmonary arterial hypertension (PAH) who were treatment naïve or previously received monotherapies, according to final…

Echocardiogram (ECG) measures that indicate the heart’s right ventricle (RV) and the pulmonary arteries are working poorly together to send blood to the lungs may help predict the presence of pulmonary hypertension (PH) in people with a certain type of heart failure, a recent publication indicates.